Wednesday, August 10, 2022


Ingenza Awarded Government Funding

To develop novel carbon capture technology

Latest Posts

New Study Highlights Superior Efficacy of At-home Dry EEG assessment Compared to Lab-based Monitoring

Results indicate that easy-to-use task-driven EEG can yield clinical-grade data in large-scale, real-world investigations in neuroscience with extremely high adherence rates.

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

“We are excited to further advance the development of GDA-201, a NAM-enabled natural killer (NK) cell therapy candidate which we believe has the potential to be a new readily available, cryopreserved treatment option for cancer patients with relapsed/refractory lymphoma,” said Ronit Simantov, M.D., chief medical and scientific officer of Gamida Cell.

Akadeum Life Sciences Announces New Dead Cell Removal Kit Using Microbubble Technology

Akadeum Life Sciences advises that the new buoyant separation method creates a more effective way for researchers to use valuable samples with a higher retention rate of viable cells than current magnetic techniques.

Bio-Rad Extends Range of StarBright Violet and UltraViolet Dyes for Multiplex Flow Cytometry

StarBright Violet 760, StarBright UltraViolet 575, and StarBright UltraViolet 605 dyes conjugated to highly validated antibodies for multicolor panel design in immunology research.

Ingenza announced that its recent partnership with Johnson Matthey has been selected to receive vital funding of £441,632.88 from the Department of Business, Energy and Industrial Strategy as part of the £1 billion fund from the Net Zero Innovation Portfolio to slash emissions and energy costs.

Ingenza advises the project aims to develop a novel CO2 conversion technology, which will capture industrial CO2 emissions and convert them into formate, a versatile chemical that can be used across various industries, including pharmaceuticals and agriculture.

This venture will build on the success of the existing partnership between Ingenza and Johnson Matthey, bringing together the unique expertise of each team to make carbon capture technology a feasible and appealing solution for industry. As a world leader in industrial biotechnology, Ingenza will develop a bespoke engineered biocatalyst that will allow efficient hydrogenation of industrial CO2 emissions into formate. Johnson Matthey will then develop these biocatalysts into a cost competitive and scalable format for industry. This solution aims to encourage the adoption of carbon capture technologies by converting industrially emitted CO2 into a valuable and versatile commodity chemical that can be sold on for a profit, while simultaneously reducing the emissions that leak into the atmosphere.

Reuben Carr, Head of Chemical Biology at Ingenza, commented: “We are delighted to receive this funding and support from the government, which will be instrumental in our development of a carbon capture technology for the waste that industry produces. We look forward to working with Johnson Matthey to deliver on this project.”

Fraser Brown, Head of Chemistry at Ingenza, added: “This is a fantastic opportunity to work with the Johnson Matthey team again and draw on their chemical engineering expertise. Together, we will turn industrial CO2 into a platform chemical feedstock, encouraging industry everywhere to invest in sustaining the planet.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine